SLC5A2 and chronic kidney disease: In this particular CKD cohort, where taking SGLT-2 inhibitors was simulated with glucose spiking, interference from the highest level of glucose concentration led to 5.1% (17/333) and 1.8% (6/333) of samples having uACR underestimates of ≥10% and ≥20%, respectively (Supplementary Table S3).